GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alexion Pharmaceuticals Inc (NAS:ALXN) » Definitions » Days Inventory

Alexion Pharmaceuticals (Alexion Pharmaceuticals) Days Inventory : 574.71 (As of Mar. 2021)


View and export this data going back to 1996. Start your Free Trial

What is Alexion Pharmaceuticals Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Alexion Pharmaceuticals's Average Total Inventories for the three months ended in Mar. 2021 was $790 Mil. Alexion Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2021 was $125 Mil. Hence, Alexion Pharmaceuticals's Days Inventory for the three months ended in Mar. 2021 was 574.71.

The historical rank and industry rank for Alexion Pharmaceuticals's Days Inventory or its related term are showing as below:

ALXN' s Days Inventory Range Over the Past 10 Years
Min: 202.61   Med: 402.97   Max: 508.92
Current: 447

During the past 13 years, Alexion Pharmaceuticals's highest Days Inventory was 508.92. The lowest was 202.61. And the median was 402.97.

ALXN's Days Inventory is not ranked
in the Biotechnology industry.
Industry Median: 192.335 vs ALXN: 447.00

Alexion Pharmaceuticals's Days Inventory increased from Mar. 2020 (496.03) to Mar. 2021 (574.71). It might indicate that Alexion Pharmaceuticals's sales slowed down.

Inventory Turnover measures how fast the company turns over its inventory within a year. Alexion Pharmaceuticals's Inventory Turnover for the three months ended in Mar. 2021 was 0.16.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Alexion Pharmaceuticals's Inventory-to-Revenue for the three months ended in Mar. 2021 was 0.48.


Alexion Pharmaceuticals Days Inventory Historical Data

The historical data trend for Alexion Pharmaceuticals's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alexion Pharmaceuticals Days Inventory Chart

Alexion Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Days Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only 469.64 335.55 454.86 508.92 462.70

Alexion Pharmaceuticals Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Days Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 496.03 366.67 412.01 451.06 574.71

Competitive Comparison of Alexion Pharmaceuticals's Days Inventory

For the Biotechnology subindustry, Alexion Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alexion Pharmaceuticals's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alexion Pharmaceuticals's Days Inventory distribution charts can be found below:

* The bar in red indicates where Alexion Pharmaceuticals's Days Inventory falls into.



Alexion Pharmaceuticals Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Alexion Pharmaceuticals's Days Inventory for the fiscal year that ended in Dec. 2020 is calculated as

Days Inventory (A: Dec. 2020 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (A: Dec. 2019 ) + Total Inventories (A: Dec. 2020 )) / count ) / Cost of Goods Sold (A: Dec. 2020 )*Days in Period
=( (627.6 + 775.7) / 2 ) / 553.5*365
=701.65 / 553.5*365
=462.70

Alexion Pharmaceuticals's Days Inventory for the quarter that ended in Mar. 2021 is calculated as:

Days Inventory (Q: Mar. 2021 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (Q: Dec. 2020 ) + Total Inventories (Q: Mar. 2021 )) / count ) / Cost of Goods Sold (Q: Mar. 2021 )*Days in Period
=( (775.7 + 803.9) / 2 ) / 125.4*365 / 4
=789.8 / 125.4*365 / 4
=574.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alexion Pharmaceuticals  (NAS:ALXN) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Alexion Pharmaceuticals's Inventory Turnover for the three months ended in Mar. 2021 is calculated as

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Alexion Pharmaceuticals's Inventory to Revenue for the three months ended in Mar. 2021 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.


Alexion Pharmaceuticals Days Inventory Related Terms

Thank you for viewing the detailed overview of Alexion Pharmaceuticals's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Alexion Pharmaceuticals (Alexion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
121 Seaport Boulevard, Boston, MA, USA, 02210
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.
Executives
Daniel Bazarko officer: SVP, Controller, CAO C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD BOSTON MA 02210
Tanisha Carino officer: EVP & CCAO C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210
Anne-marie Law officer: EVP, Chief Experience Officer C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Brian Goff officer: EVP & Chief Commercial Officer C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John J Orloff officer: EVP, Research & Development C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Indrani Lall Franchini officer: EVP, Chief Compliance Officer C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John T Mollen director 176 SOUTH STREET HOPKINTON MA 01748
David R Brennan director C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Baker Bros. Advisors (gp) Llc director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Andreas Rummelt director C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE CHESHIRE CT 06410
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Baker Brothers Life Sciences Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Deborah Dunsire director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Judith A Reinsdorf director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974

Alexion Pharmaceuticals (Alexion Pharmaceuticals) Headlines

From GuruFocus

Alexion to Report First Quarter 2021 Results on Monday, May 3, 2021

By Business Wire Business Wire 04-20-2021

Alexion Pharmaceuticals Stock Appears To Be Fairly Valued

By GF Value GF Value 04-04-2021